L'intérêt à découvert pour KKR Real Est Finance Tr donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de KKR Real Est Finance Tr. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

KKR Real Est Finance Tr (NYSE:KREF) Stock, Rapport sur les intérêts à découvert

KKR REAL ESTATE FINANCE TRUS

KKR Real Estate Finance

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

Biotech

News

Health Care

General

ADAG

Adagene Has Received Written Feedback From The FDA On Its Clinical Development Plan To Evaluate Muzastotug (ADG126) In Combination With Merck's Keytruda For Microsatellite Stable Colorectal Cancer, Patients Enrollment In Phase 2 To Start In 2H 2025

Accelsius, a leader in advanced data center cooling solutions, announced that its proprietary NeuCool&#x2122; IR80 system will be deployed in Q3 2025 at Equinix's Co-Innovation Facility (CIF) in the DC15 International Business Exchange&#x2122; (IBX&#xAE;) data center at the Equinix Ashburn Campus. This dedicated facility provides a platform for Equinix to work with companies that are developing innovative technologies, helping customers see and experience these solutions in action.

Innventure's Accelsius Teams Up with Equinix to Showcase NeuCool IR80 System at Virginia Data Hub

Piper Sandler analyst Derek Podhaizer downgrades Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Overweight to Neutral and maintains the price target from $16 to $16.

Downgrades

Price Target

Analyst Ratings

AESI

Piper Sandler Downgrades Atlas Energy Solutions to Neutral, Maintains Price Target to $16

Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>)(TSX:<a class="ticker" href="https://www.benzinga.com/stock/URE#TSX">URE</a>) (the "Company" or "Ur-Energy") is pleased to provide an update on Q2 2025 operational and construction progress at its Lost Creek and Shirley Basin in situ uranium projects in Wyoming.
Lost Creek Production and Sales
At our flagship Lost Creek Project, production operations continue to progress with a full operations team on site. Most recently, the construction and startup of header house 2-15 was completed, demonstrating the team's growing efficiency and skill. With training and experience building, our production growth trajectory remains positive.
During the second quarter of 2025, we dried and packaged 112,033 pounds of U3O8, representing a 35% increase over the first quarter 2025;
We shipped 105,316 pounds of powdered uranium concentrate, also known as "yellowcake," to the conversion facility;
At quarter end, our finished inventory at the conversion facility was 315,607 pounds U3O8, and the in-process and drummed inventory at Lost Creek totaled approximately 55,000 pounds U3O8.
In Q2 2025 we sold 165,000 pounds U3O8 at an average price of $63.20 per pound for revenue of $10.4 million.

TSX:URE

Ur-Energy Reports Dried And Packaged 112,033 Pounds Of U3O8 In Q2, Up 35% Over Q1 2025; Co Sells 165K Pounds U3O8 In Q2 At Average Price Of $63.20 Per Pound For Revenue Of $10.4M

LASE

Laser Photonics' CMS Laser Wins New Order From EAP Lasers For Custom CO₂ Drilling System, Signals Strong U.S. Demand

Contracts

ELVA

Electrovaya Receives Additional $4.5M Order Through Its OEM Channel

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), the global leader in delivering and securing every app and API, today announced new tools to reduce the immense complexity cross-functional operations (XOps) teams face in managing hybrid, multicloud, and AI-driven application environments. F5 AI Assistant now provides a single natural language interface across F5 BIG-IP, F5 NGINX One, and F5 Distributed Cloud Services offerings to unify the user experience throughout the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.f5.com%2Fproducts%2Ff5-application-delivery-and-security-platform&amp;esheet=54290346&amp;newsitemid=20250715307495&amp;lan=en-US&amp;anchor=F5+Application+Delivery+and+Security+Platform&amp;index=1&amp;md5=d9a5cdfe76272500396bc275242d36bf">F5 Application Delivery and Security Platform</a> (ADSP). As a new feature for the AI Assistant, F5 iRules code generation introduces a scalable, automated solution for teams at all levels of expertise to customize and program solutions for their specific environments.
As organizations increasingly deploy distributed applications and adopt AI solutions, they face increasing pressure to simplify workflows while scaling operations in a fast-evolving digital ecosystem. F5 AI Assistant with iRules code generation helps customers streamline operations by easing configurations, optimizing processes, and unlocking programmability to elevate enterprise application and security management.

FFIV

F5 Launches AI Assistant to Simplify App Management Across Multicloud and AI Systems

MARA

MARA Leads $20M Investment In Two Prime, Expands Bitcoin Allocation To 2,000 BTC To Boost Institutional Yield Strategy

Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health Canada has granted the Company a meeting to discuss Aquestive's planned New Drug Submission (NDS) for Anaphylm&#x2122; (epinephrine) Sublingual Film in Canada. In addition, the Company has submitted an initial briefing book to the European Medicines Agency (EMA). The Company plans to submit a Marketing Authorization Application (MAA) to the EMA as soon as possible.
"These regulatory activities mark the pivotal first steps in Aquestive's comprehensive ex-U.S. regulatory strategy," said Dan Barber, President and Chief Executive Officer of Aquestive. "With our U.S. FDA New Drug Application recently accepted and a PDUFA target action date of January 31, 2026 established, we're now positioned to pursue parallel regulatory pathways with the potential to bring needle-free, device-free Anaphylm to patients underserved by current treatment options. Our proven ability to successfully bring innovative therapies to market globally, combined with our oral epinephrine approach, positions us to fundamentally change how patients and caregivers manage severe allergic reactions, including anaphylaxis."
Aquestive brings significant regulatory and commercialization experience to this expansion effort, with six FDA-approved drugs in its portfolio and products currently available across six continents. This established global footprint and regulatory track record positions the Company to efficiently navigate international approval processes.
Unlike traditional epinephrine auto-injectors that require needles, Anaphylm&#x2122; is administered orally, addressing critical barriers to treatment, including needle phobia, device malfunction concerns, and portability challenges that affect patient compliance and emergency response.
The Company's ex-U.S. regulatory strategy prioritizes markets with significant unmet medical needs and regulatory frameworks conducive to innovative therapies. EMA and Canada represent ideal initial international markets given their collaborative regulatory environment and substantial population of patients requiring reliable anaphylaxis treatment options.
Aquestive will continue to provide updates on its global regulatory approval progress as it works to establish Anaphylm as the new standard of care for the treatment of severe allergic reactions and anaphylaxis worldwide.

AQST

Aquestive Seeks Approval for Needle-Free Allergy Film in Canada and Europe, Eyes Global Expansion

TECH

Bio-Techne Partners To Distribute Spear Bio's Ultrasensitive Immunoassays, Enabling The Detection Of Low-abundance Biomarkers In Neurology, This Partnership Follows Bio-Techne's Participation In Spear Bio's $45M Series A Funding Round In 2024

JP Morgan analyst Adrian Huerta initiates coverage on Amrize (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRZ#NYSE">AMRZ</a>) with a Overweight rating and announces Price Target of $57.

Initiation

AMRZ

JP Morgan Initiates Coverage On Amrize with Overweight Rating, Announces Price Target of $57

GXO Signs Multi-Year Logistics Deal With Sky Italia To Manage Supply Chain, Storage, And Value-Added Services At Colleferro Site

Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) ("Acuren") today announced the expiration of the 60-day "go-shop" period ("Go-Shop Period") in connection with the previously announced Agreement and Plan of Merger with NV5 Global, Inc. (("NV5", NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), dated as of May 14, 2025 (the "Merger Agreement").
During the Go-Shop Period, NV5 was permitted to solicit and enter into negotiations with third parties that made a proposal or offer to acquire NV5. The Go-Shop Period expired at 11:59 p.m. ET on July 14, 2025. NV5 did not receive an NV5 Superior Proposal (as such term is defined in the Merger Agreement) during the Go-Shop Period.
The transactions contemplated by the Merger Agreement (the "Transactions") are expected to close in August of 2025, subject to customary closing conditions, including approval of each of Acuren and NV5's stockholders and receipt of regulatory approvals.

NVEE

Acuren Announces Expiration Of 60-Day "Go-Shop" Period In Connection With Agreement And Plan Of Merger With NV5 Global

SXTP

60 Degrees Pharmaceutical Determines Maximum Size Of Commercial Market For ARAKODA In Human Babesiosis To Be 380,000 Patients And $245M In Sales Annually

RFIL

RF Industries Secures $2.3M Follow-On Orders From Leading Aerospace Firm For Mission-Critical Custom Cabling Solutions

<ul>
<li>Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technology</li>
<li>Preclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer's disease</li>
<li>Agreement follows more than one year of engagement to assess technical feasibility and profile series of development candidates &nbsp;</li>
</ul>

ABOS

Acumen Pharmaceuticals Agrees With JCR Pharmaceuticals To Develop An Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimer's, JCR Will Receive An Upfront Payment And Will Be Eligible For An Additional Option Payment Should Acumen Exercise Its Exclusive Option To Develop Up To Two Development Candidates

Momentum builds behind global expansion strategy as brand aims to accelerate global net unit growth to achieve 2,000 international restaurants by 2028
DUBLIN, Ohio, July 15, 2025 /PRNewswire/ --&nbsp;The Wendy's Company announced today the finalization of two new franchise agreements that will add up to 190 new Wendy's&#xAE; restaurants across Italy and Armenia, marking a significant step forward in advancing the brand's strategic priority to accelerate global net unit growth. These commitments support Wendy's goal to achieve 70 percent of its unit growth outside the United States, with the Company expecting to reach 2,000 international restaurants by 2028.

Wendy's Company Finalizes Two New Franchise Agreements That Will Add Up To 190 New Wendy's Restaurants Across Italy And Armenia

Valvoline Releases FY24 Impact Report, Highlights Green Energy Push, Record Donations, And 2,000th Store Milestone

The agreement with Sky Italia, part of one of the leading entertainment groups in Europe, includes supply chain management and strategic value-added activities
MILAN, Italy, July 15, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=VQl4LAqgGyd9DAs3ChJKVgCOG3jJVMXJf83TR8fSjn1e9TnAkisxlkiSDIdZWeKygrZ5BuDOmxuspQHtjz4Cfg==">GXO Logistics, Inc.&nbsp;</a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), the world's largest pure-play contract logistics provider, announced today that it has signed a multi-year agreement with Sky Italia, Italy's leading media &amp; entertainment company and a European entertainment leader. The agreement involves managing Sky's supply chain from the GXO warehouse in Colleferro where Sky's Business Core products (decoders and routers) and the Glass line (Smart TV) will be stored, as well as all the merchandising related to the Sky brand and TV series.

GXO Logistics Signs Multi-Year Agreement With Sky Italia For Supply Chain Management And Strategic Value-Added Activities In Italy

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is down nearly 5% from its all-time high of $122,838, trading at $116,880 as of Tuesday morning European time, as the <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46388685/bitcoin-shatters-all-time-high-to-hit-123000-as-ethereum-cracks-3000-and-xrp-taps-3">broader crypto market pauses</a> ahead of key macroeconomic data and reacts to a spike in large-scale on-chain activity. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has also dipped, down 2.5% to around $2,980.
What Experts Are Saying: Speaking with Benzinga, analysts say the move is largely a correction following a rapid run-up, compounded by heightened uncertainty around U.S. inflation data and growing signs of profit-taking by major holders.
"It's expected that after a large run, some correction is likely, especially following an uninterrupted move from $108K to $122K," said Nicolai Sondergaard, Research Analyst at Nansen. "We now see quite some heavy liquidation levels around $116.3K which is something to watch next as an immediate psychological level."
On-chain <a href="https://cryptoquant.com/insights/quicktake/68750927d04021572872b1f1-As-Retail-Chases-New-Highs-Whales-Are-Preparing-to-Sell-on-Binance?utm_source=telegram&amp;utm_medium=sns&amp;utm_campaign=quicktake&amp;utm_content=crazzyblockk">data</a> from CryptoQuant confirms that whales—large Bitcoin holders—have begun repositioning.
According to the firm, over 1,800 BTC were deposited onto Binance in a single day, with transactions over $1 million accounting for more than 35% of total inflows. 
These movements are typically viewed as precursors to increased volatility.
"This activity on Binance is a critical market signal," the firm noted, citing the exchange's dominant position in global spot and derivatives trading. 
The whale inflows suggest either profit-taking after the rally or preparations to hedge against downside risk ahead of CPI data.
Bitfinex analysts attributed the pullback to a combination of factors, including the recent rally's exhaustion and caution ahead of U.S. inflation figures due later today. "Bitcoin's recent pullback appears to be a natural breather following fresh all-time highs, alongside a cautious wait-and-see stance ahead of today's CPI release."
They added that if core inflation exceeds 3.2%, it could delay Federal Reserve easing, lift the dollar, and put pressure on risk assets like Bitcoin. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46394828/bitcoin-eth-xrp-solana-are-in-for-a-long-and-exhausting-bull-market-bernstein-predicts">Bitcoin, ETH, XRP, Solana Are In For A &#8216;Long And Exhausting Bull Market,&#8217; Bernstein Predicts</a>
"That would strengthen the dollar and hurt demand for non-yielding assets like Bitcoin, potentially extending the pullback by another 5–10%, based on prior CPI events."
On the other hand, a softer-than-expected print—such as a headline figure below 2.5% and core easing toward 2.9%—could revive bullish momentum. 
"A similar outcome today could push Bitcoin back toward $120K+ again especially if ETF inflows remain strong as they have in the past 2 weeks," Bitfinex said.
Longer term, structural factors such as U.S. tariffs could keep CPI elevated near 2.9%, which analysts say may limit the scale or duration of any policy-driven rally.
Altcoin markets, which had shown renewed strength following Bitcoin's recent high, are also under pressure. 
Ryan Lee, Chief Analyst at Bitget Research, pointed to a typical capital rotation pattern: "The recent surge in altcoins following Bitcoin's all-time high reflects a classic capital rotation pattern, as traders seek higher beta plays after BTC's initial breakout."
Lee said Ethereum could range between $2,500 and $3,500 in Q3 depending on DeFi activity and ETF momentum, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) trajectories will depend on network growth and regulatory outcomes respectively.
What&#8217;s Next: Market experts suggest that the next move for Bitcoin and by extension, the rest of the crypto market, will hinge on today's inflation data and how it influences interest rate expectations.
Whale behavior and ETF flows will also remain key variables.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46392541/how-donald-trumps-big-beautiful-bill-was-a-big-beautiful-boost-for-bitcoin">How Donald Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Was A &#8216;Big Beautiful Boost&#8217; For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$XRP

Bitcoin Dips Below $117,000: What On-Chain Data Reveals About The Next Big Price Shift

Press Releases

KKR Real Estate Finance Trust Inc. Reports Fourth Quarter 2024 Results

KKR Real Estate Finance Trust Inc. to Present at Citi's 30th Annual Global Property CEO Conference

KKR Real Estate Finance Trust Inc. Announces Closing of New $550 Million Senior Secured Term Loan B

KKR Real Estate Finance Trust Inc. Declares Quarterly Dividend of $0.25 Per Share of Common Stock

KKR Real Estate Finance Trust Inc. to Announce First Quarter 2025 Results

KKR Real Estate Finance Trust Inc. Announces Time Change for its Conference Call to Discuss First Quarter 2025 Results

Comments

KKR Real Est Finance Tr

Intérêt court

KKR Real Est Finance Tr (NYSE:KREF) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL